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Abstract
We present a model to optimise a vaccination campaign aiming to prevent or to curb a Zika
virus outbreak. We show that the optimum vaccination strategy to reduce the number of
cases by a mass vaccination campaign should start when the Aedes mosquitoes’ density
reaches the threshold of 1.5 mosquitoes per humans, the moment the reproduction number
crosses one. The maximum time it is advisable to wait for the introduction of a vaccination
campaign is when the first ZIKV case is identified, although this would not be as effective to
minimise the number of infections as when the mosquitoes’ density crosses the critical
threshold. This suboptimum strategy, however, would still curb the outbreak. In both
cases, the catch up strategy should aim to vaccinate at least 25% of the target population
during a concentrated effort of 1 month immediately after identifying the threshold. This
is the time taken to accumulate the herd immunity threshold of 56.5%. These calculations
were done based on theoretical assumptions that vaccine implementation would be feasible
within a very short time frame.
Introduction
Since its introduction in the Brazilian Northeastern cities of Recife and Salvador in 2014 by
travellers from French Polynesia [1], the mosquito-borne flavivirus Zika virus (ZIKV) spread
rapidly and in less than a year, cases emerged throughout South America and the Caribbean,
and in parts of North America. ZIKV has raised global concerns due to its association with
birth defects and Guillain–Barré syndrome [2]. The magnitude of ZIKV outbreaks in the
Pacific region and in particular in Brazil in 2015, led the World Health Organization to declare
ZIKV a ‘Public Health Emergency of International Concern’ [3].
Zika also affected travellers [4–9]. The rapid spread of ZIKV via travellers to other
American countries, where it caused an estimated 1.9 million infections [10, 11], including
its potential spreading to Europe [12, 13], has spurred the search for an effective vaccine [14].
The list of candidate vaccines has reduced from 45 in 2017 to only 12 in the test, with three
candidates in phase II evaluation [15]. The candidates are based on neutralizing antibodies by
nucleic acid vaccines, inactivated virions and live and attenuated virus, all with the objective of
stimulating neutralisation antibodies against antigens in the surface of the virion [16]. Other
ZIKV vaccine developments are based on antibodies derived from dengue infection, which
showed neutralisation potential against ZIV [7]. DNA vaccines are particularly interesting
because they have the potential to be rapidly scaled-up and deployed during an outbreak
should they prove to be efficacious. DNA vaccines work by creating a plasmid (a circle of
DNA) that encodes the genes for the virus’s envelope proteins. Once this plasmid makes its
way into the nucleus of the target cell, the cell’s own molecular machinery begins producing
the viral proteins, which then induce an immune response [17].
However, the brief nature of the 2015–2016 outbreaks is making wide-scale testing of
the new vaccines difficult and some research/development programmes have already
been curtailed [18, 19]. Even if an effective vaccine against ZIKV manages to reach the
market in the near future, many questions remain to be answered. Should a vaccine be
introduced in response to an imminent outbreak or should it be introduced in the routine
immunisation programme? In the case of an outbreak vaccine, when should it be intro-
duced and for how long? In the case of a routine vaccine, which age should be targeted?
For the time being, WHO has only developed a target product profile for a Zika vaccine
for outbreak use [20].
We aim to address the scenario of an outbreak use of Zika vaccines. In particular, we aim to
determine the optimum time point to introduce a mass vaccination campaign in response to an
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outbreak, the thresholds to declare an outbreak, the optimum dur-
ation of such a strategy and the coverage needed to avert an outbreak.
Methods
The method used to answer the questions of when to trigger a
ZIKV vaccine in response to an outbreak and how long should
a vaccination campaign last consists of:
1) Fitting the incidence of dengue in an area relatively free of
ZIKV. We have chosen the city of Rio de Janeiro in the year
between October 2011 and September 2012;
2) From the fitted incidence of dengue, we calculated the total
number of Aedesa egypti mosquitoes according to the methods
detailed in [21, 22];
3) The number of Aedes mosquitoes in the chosen are and the
period was used in a dynamical model detailed below to esti-
mate how different vaccination schemes would minimise the
number of ZIKV cases in case of an outbreak. We modelled
the optimum moment to introduce the vaccine and the opti-
mum duration of a vaccination campaign.
Outbreak use of a vaccine with entomological indices as a
trigger
We begin by fitting a continuous function, denoted
IncidenceDENV(t), to the number of reported ZIKV cases. The
incidence data were fitted to the chosen function [21, 22]:
IncidenceDENV(t) = c1 exp − (t − c2)
2
c3
[ ]
+ c4 (1)
representing the time-dependent dengue infection incidence. In
equation (1) c1 is a scale parameter that determines the maximum
incidence, c2 is the time at which the maximum incidence is reached,
c3 represents the width of the time-dependent incidence function
and c4 is just another scaling parameter. Equation (1) is intended
to reproduce a ‘Gaussian’ curve and so c1 and c4 are just scale para-
meters but c2 represents the ‘mean’ (and mode or maximum) time
and c3 represents the ‘variance’ of the time distribution of cases. All
parameters ci, i = 1, …, 4 were fitted to model (1) by the Bootstrap
method [23] the results of which are shown in Table 1.
Figure 1 illustrates the fitting of equation (1) to the incidence
data of ZIKV in Salvador in 2015.
Next, we calculated the total number of Aedes mosquitoes in
Salvador in 2015 according to the method detailed in [21, 22].
We begin by defining the incidence as the product of the force of
infection, λ(t), times the number of susceptible individuals, SH(t).
The force of infection is defined as λ(t) = (abIM(t))/(NH(t)), where
NH(t) denotes the total human population, a is the mosquitoe
biting rate, b is the fraction of those bites produced by the infec-
tious mosquitoes IM(t) that are infective to susceptible humans
SH(t). All the parameters used in these calculations and in the
model simulations are shown in Table 2 and were obtained by
the Latin Hypercube method [24] that best reproduced the
ZIKV outbreak in Salvador in 2015.
From the fitted incidence, IncidenceDENV(t) we calculate the
number of infective mosquitoes
IM(t) = IncidenceDENV(t)NH(t)abSH(t) ,
where SH(t) is the entire Salvador population in 2015. From the
number of infectious mosquitoes, we calculated the number of
latent mosquitoes, LM(t), given by
LM(t) = 1
gM
d
dt
IM(t) + mMIM(t)
[ ]
,
where 1/γM is the average duration of the extrinsic incubation
period and μM is the natural mortality rate of mosquitoes.
The number of susceptible mosquitoes is given by
SM(t) = NHacIH(t)
d
dt
LM(t) + (mM + gM)LM(t)
[ ]
,
where c is the fraction of the mosquitoes that bite infective
humans and acquire the infection, and IH(t) is the number of
humans infected with dengue. The estimated total number of
mosquitoes is NM(t) = SM(t) + LM(t) + IM(t). We are going to
need the derivatives of these functions:
dNM(t)
dt
= dSM(t)
dt
+ dLM(t)
dt
+ dIM(t)
dt
(2)
From the total mosquitoes’ population curve, we calculate the
mosquitoes’ densities, m(t), defined as the ratio between the num-
ber of mosquitoes with respect to the human population. The
mosquitoes’ density is one of the components of the Effective
Reproduction Number, R(t), such that:
R(t) = m(t)a
2bcgM
mM(mM + gM)(mH + gH)
SH(t)
NH(t) (3)
From equation (3) it is possible to estimate the critical value of
the mosquitoes’ density, mcrit, that would guarantee that R0 > 1,
that is:
mcrit = NHSH(tcrit) k, (4)
where
k = mM(mH + gH)(mM + gM)
a2bcgM
. (5)
Figure 2 shows the fitted incidence of ZIKV in Salvador (2015)
along with the curves of the Effective Reproduction Number, R(t),
and the mosquitoes’ densities m(t).
Outbreak use of a vaccine with human cases as a trigger
It can be noted from Figure 2 that R(t) crosses the unit threshold
at mcrit(t) slightly below 1.5 mosquitoes per human. This value
Table 1. Parameters’ values (mean, lower bound and upper bound) fitted to
equation (1) to ZIKV incidence in Salvador 2015 by Bootstrap technique [23]
Parameter Mean Lower bound Upper bound
c1 10 982 10 075 11 937
c2 7.2362 7.1716 7.2872
c3 3.7351 2.3715 4.0633
c4 278.296 257.681 301.512
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will be used to determine the critical moment and a preventative
vaccine should be introduced. For this we have chosen the case of
the city of Rio de Janeiro for the dengue season of 2011–2012, the
year with the highest dengue incidence in history so far. From
dengue incidence in that period, we calculated the total number
of Aedes mosquitoes in order to determine the critical moment
the mosquitoes’ densities crossed the 1.5 mosquitoes per human
threshold. That should be the moment when in case ZIKV-
infected travellers arrival could trigger a ZIKV outbreak. It should
be, therefore, the moment to introduce the preventative vaccine in
the form of a universal campaign aiming both sexes and all age
groups. We are assuming that the critical mosquitoes’ densities
for Salvador and Rio de Janeiro are the same because the basic
reproduction number of Zika for both cities is quite similar in
value (2.33; CI 1.97–2.97 for Rio de Janeiro [25] and 2.1; CI
1.8–2.5 for Salvador [26]).
The mosquitoes’ densities for Rio de Janeiro in 2011–2012
were calculated by the same method as described above for
Salvador in 2015, by fitting the dengue incidence data to equa-
tion (2) and then proceed with the calculations described
above. The fitting parameters to dengue incidence are described
in Table 3.
Figure 3 illustrates the case of 2011–2012, the years with the
outbreak with the highest incidence of dengue in the history of
Rio de Janeiro, Brazil.
Figure 4 shows the dengue incidence fitted to equation (1) and
the mosquitoes’ density calculated from the total number of
mosquitoes.
It can be noted from Figure (4) that at week 16 the mosquitoes’
density crosses the threshold 1.5 mosquitoes per humans. From
this moment onwards, ZIKV virus could invade Rio de Janeiro
and would be the optimum time to introduce a preventative
vaccine.
The populations involved in the transmission are human
hosts and mosquitoes. Therefore, the population densities per
unit area are divided into the compartments/variables described
in Table 4.
The parameters appearing in the model are defined in Table 2.
The model assumes that one or more ZIKV-infected travel-
lers arrive at the previously unaffected area at time tx and remain
infected for an average period of 1/(μH + γH) months, after
which they either die or recover from the infection, that is
ITH(t) = ITH(0) exp [−(mH + gH)(t − tx)]u(t − tx). This assump-
tion is necessary only to model Zika introduction into the
system.
Fig. 1. Fitting a function (eq. 1) to ZIKV incidence of
infections in Salvador in 2015. Continuous line repre-
sents the mean curve whereas the finely dotted line
the 95% CI.
Table 2. Model parameters, biological meaning and values. The dimension of
rates is months−1
Parameter Meaning Mean
a A. aegypti biting rate 25.400
bdengue Fraction of bites actually infective to
humans (dengue)
0.700
μH Human natural mortality rate 1.096 × 10
−3
γH−D Dengue recovery rate 1.500
γM−D Latency rate in mosquitoes for
dengue
4.000
γH−ZIKV ZIKV recovery rate 1.500
γM−ZIKV Latency rate in mosquitoes for ZIKV 4.000
μM Natural mortality rate of mosquitoes 2.330
cdengue A. aegypti susceptibility to dengue 0.700
bZIKV Fraction of bites actually infective to
humans (ZIKV)
0.610
cZIKV A. aegypti susceptibility to ZIKV 0.530
rH Humans reproduction rate 0.017
KH Humans carrying capacity 7.000 × 10
6
g Proportion of ZKV-infected mothers 0.500
p Proportion of ZIKV-infected babies
who develop Zika congenital
syndrome
0.060
αH Death rate of babies with Zika
congenital syndrome
5.000 × 10−3
σ Rate of microcephaly development 8.000
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The model is described by the following set of equations:
dNH(t)
dt
= rH 1− NH(t)KH
[ ]
[SH(t) + RH(t) + gIH(t)] − mHNH(t)
dSH(t)
dt
= −abIM(t) SH(t)NH(t) − mHSH(t)
+ rH 1− NH(t)KH
[ ]
[SH(t) + RH(t) + gIH(t)]
− ySH(t)u(t − t0)u(t1 − t)
dIH(t)
dt
= abIM(t) SH(t)NH(t) − (mH + gH)IH(t)
dRH(t)
dt
= gHIH(t) − mHRH(t)
dVH(t)
dt
= ySH(t)u(t − t0)u(t1 − t) − mHVH(t)
dBH(t)
dt
= rH 1− NH(t)KH
[ ]
[(1− g)IH(t)]
− psBH(t) − (1− p)gHBH(t)
dRB(t)
dt
= (1− p)gHBH(t) − mHRB(t)
dMH(t)
dt
= psBH(t) − (mH + aH)MH(t)
dSM(t)
dt
= −acSM(t) [IH(t) + I
T
H(t)]
NH(t) + mM[LM(t) + IM(t)]
+ dNM(t)
dt
dLM(t)
dt
= acSM(t) [IH(t) + I
T
H(t)]
NH(t) − (mM + gM)LM(t)
dIM(t)
dt
= gMLM(t) − mMIM(t)
ITH(t) = ITH(0) exp[−(mH + gH)(t − tx)]u(t − tx)
NM(t) = SM(t) + LM(t) + IM(t),
(6)
where θ(t− tx) is the Heaviside step function introduced to mimic
the moment the vaccination starts and the moment an infected
traveller arrives in the area (tx). The latter varied along the
model simulations.
For the initial conditions, we assumed that before Zika was
introduced in Rio de Janeiro, the population was at steady state,
such that SH(0) =KH((rH− μH)/rH). The other initial values
assumed were ITH(0) = 10, and all the remaining values were set
equal to zero. The human carrying capacity was set as equal to
the total population of Rio de Janeiro, that is KH = 6.32 × 10
6. We
are well aware that the time period where the strategies are designed
is very short where one would not expect density-dependent demo-
graphic effects to be important. Notwithstanding, we considered a
logistic grow for the human populations for the sake of complete-
ness of the model.
Let us explain in detail the dynamics of each described by
system (6).
The total human population, NH(t), grows by births, expressed
in the positive term of the first equation of system (6),
rH 1− NH(t)KH
[ ]
[SH(t) + RH(t) + gIH(t)]
and decreases by natural deaths (i.e. deaths by other causes not
related to ZIKV infection), the negative term μHNH(t). Note
that all susceptible and recovered individuals reproduce but
only a fraction g of the infected contributes to the next generation
of humans.
Fig. 2. ZIKV incidence of infections in Salvador in 2015
(continuous line), Effective Reproduction Number (finely
dotted line) and the mosquitoes’ density (grossly dotted
line). The thin line represents the threshold for transmis-
sion whereas the very thin line the critical mosquitoes’
density that marks the moment R(t) crosses 1 from
below and from above. The simulation used the para-
meters as in Table 2.
Table 3. Parameters’ values (mean, lower bound and upper bound) fitted to
equation (1) to dengue incidence in Rio de Janeiro 2011–2012 by Bootstrap
technique [23]
Parameter Mean Lower bound Upper bound
c1 147 144 134 944 159 879
c2 10.004 9.9147 10.073
c3 3.49035 22 158 4.0631
c4 1500.02 1388.89 1625.31
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Subpopulation of susceptible humans, SH(t), acquire the
infection from infected mosquitoes with the incidence expressed
in the first negative term of the second equation of system (6),
abIM(t) (SH(t))/(NH(t)), increases by births, expressed in the
positive term,
rH 1− NH(t)KH
[ ]
[SH(t) + RH(t) + gIH(t)],
and is reduced by natural deaths, the second negative term,
μHSH(t), or vaccination, the third negative term, υ SH(t)θ(t− t0)θ
(t1− t). The two θ functions, θ(t− t0)θ(t1− t), were included to
simulate a square pulse that begins at t0 and last for (t1− t0)
time units.
The infected humans’ compartment IH(t) grows by the inci-
dence of the infection, the positive term of the third equation
in system (6), abIM(t) (SH(t))/(NH(t)), and is reduced by deaths
or recovery from infection, the negative term (μH + γH)IH(t).
Recovered humans, RH(t), come from the infected with the
recovery rate γH, the positive term in the fourth equation of sys-
tem (6) and die by natural causes with the rate μH.
Fig. 4. Dengue incidence of infections between October
2011 and December 2012 fitted to equation (1) (continu-
ous line) and the mosquitoes’ densities (grossly dotted
line). The finely dotted line represents the critical mos-
quitoes’ density threshold (1.5 mosquitoes per humans)
and the very finely dotted line the moment the mosqui-
toes’ density crosses the threshold.
Table 4. Model variables and their biological meanings
Variable Meaning
NH(t) Total human population
SH(t) Density of susceptible humans
IH(t) Density of infected humans
ITH(t) Density of ZIKV-infected travellers
RH(t) Density of recovered humans
VH(t) Density of vaccinated humans
Density of infected babies
RB(t) Density of recovered babies
MH(t) Density of congenital Zika syndrome babies
NM(t) Total Mosquitoes Population
SM(t) Density of susceptible mosquitoes
LM(t) Density of latent mosquitoes
IM(t) Density of infected and infectious mosquitoes
Fig. 3. Fitting a function (eq. 1) to dengue incidence of
infections between October 2011 and December 2012 in
Rio de Janeiro. Dots represent the notified data multi-
plied by 4, continuous line the mean fitted incidence
and dotted lines de 95% CI.
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Vaccinated humans, VH(t), come from the susceptible state
with vaccination rate υ, the positive term of the fifth equation
of system (6) and may die by natural causes with the rate μH.
Infected babies, BH(t), are born out of the fraction (1− g) of
infectedmothers, thepositive term in the sixth equationof system (6),
rH 1− NH(t)KH
[ ]
[(1− g)IH(t)],
a fraction p of whom develops the Congenital Zika Syndrome (CZS)
with rate σ, the first negative term and its complement (1−p) recover
from infection with rate γH, the second negative term.
The compartment of recovered babies, RB(t), grows with the
positive term (1− p)γHBH(t), and decreases by natural deaths
with the negative term μHBH(t).
The last human compartment, babies with CZS, MH(t), grows
with the positive term pσBH(t), and is reduced by deaths, either by
natural causes with the rate μH, or by the infection and its conse-
quences, with the rate αH.
Susceptible mosquitoes, SM(t), can acquire the infection at the
beginning of the outbreak from the infected travellers, ITH(t), and
afterwards the disease introduction, from the autochthonous
cases, IH(t), with the incidence represented by the first negative
term of the ninth equation of system,
acSM(t) [I
T
H(t) + IH(t)]
NH(t) .
The first positive term represents the births of mosquitoes,
μM[LM(t) + IM(t)], and the second positive one by the derivative
of the total mosquitoes’ population, (dNM(t))/dt, calculated
from dengue incidence data as explained above.
Once infected, mosquitoes pass to a latent state, described by
the tenth equation of system (6), whose positive term is the
incidence of the infection to mosquitoes,
acSM(t) [I
T
H(t) + IH(t)]
NH(t) ,
and the negative term composed by a rate of development of
infectiousness (the inverse of the average extrinsic incubation
period) γM, and the natural deaths of mosquitoes, μM.
Finally, the 11th equation of system (6) describes the dynamics
of infected and infectious mosquitoes, IM(t), which grows by the
evolution of the infectiousness state, γMLM(t), and diminishes by
natural deaths of mosquitoes, μMIM(t).
The total number of ZIKV cases, ZIKVcases, is given by:
ZIKVcases =
∫1
0
abIM(t) SH(t)NH(t) dt. (7)
The total number of cases is given by the integral of the inci-
dence. This does not include recovery or mortality because we are
not integrating the prevalence but rather the incidence. After a
given period, the number of cases is the sum of the number of
new cases per time unit (incidence).
We aim to maximise vaccination effectiveness, denoted Eff,
which is given by:
Eff = 1− ZIKV
after
cases
ZIKVbeforecases
, (8)
that is, 1 minus the ratio between the number of cases after vac-
cination with respect to the number of cases before vaccination.
Results
Model (6) was numerically simulated with the parameters’ values
as in Table 2 in order to obtain the moment that the vaccination
campaign should start (t0 in the second equation of system (6)),
and the duration of the campaign (t1− t0 in the second equation
of system (6)), in both cases the aim is to maximise the vaccin-
ation effectiveness. The results are shown in Figures 5 and 6. In
Figure 6, vaccination coverage Coverage was simulated from the
vaccination rate υ according to:
Coverage = 1− exp[−y(t1 − t0)]. (9)
It can be noted from Figure 5 that vaccination effectiveness is
maximised by starting the campaign as soon as possible. If the
ZIKV-infected traveller arrives at tx = 6 months (the moment
that maximises the risk of ZIKV introduction in this area), the
first ZIKV autochthonous case will appear 12 days later. This sug-
gests that the vaccine should start as soon as the first ZIKV case is
reported.
It can be noted from Figure 6 that vaccination effectiveness is
maximised by the shorter duration (1 month). In addition, the
herd immunity threshold (based on a R0≅ 2.3, as estimated by
[25]) would be reached with a lower vaccination coverage for
the 1 month campaign (∼24%) than with the 6 months campaign
(∼54%).
Therefore, the optimum vaccination strategy would be to start
a vaccination campaign at the moment the first ZIKV case is
reported and concentrate the campaign with a coverage above
25% during 1 month.
Discussion
In this work, we used the data related to the 2015 Zika outbreak in
Salvador to calculate the critical mosquitoes’ density that would
make the basic reproduction number greater than one and so allows
the infection to invade a given susceptible population. We then mod-
elled what would be the best moment to introduce a vaccine in order
to avoid the invasion of Zika infection. For this we used data from
the 2011–2012 dengue season in Rio de Janeiro to check the model’s
predictive capacity to determine the moment the mosquitoes’ density
would cross the critical value. The critical mosquitoes’ densities for
both cities were considered the same because the basic reproduction
numbers of those cities are very similar to each other.
We showed that the optimum vaccination strategy to reduce
the number of cases by a mass vaccination campaign should
start when the Aedes mosquitoes’ density reaches the threshold
of 1.5 mosquitoes per human, which means the time point
when the reproduction number goes above one. The maximum
time it is advisable to wait for the introduction of the vaccination
campaign is at most when the first ZIKV case (either autochthon-
ous or imported) is identified, although this would not be as
effective to minimise the number of infections as when the mos-
quitoes’ density crosses the critical threshold above. In both cases,
however, the catch up strategy should aim to vaccinate at least
25% of the target population during a concentrated effort of 1
month. This is the time taken to accumulate the herd immunity
threshold of 56.5%.
6 Eduardo Massad et al.
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It is important to emphasise that the model presented in this
paper is intended to be a method and the results of our simula-
tions are the only illustration of a plausible scenario. These should
not be taken as true public health policies but rather as an algo-
rithm to calculate the theoretical optimum vaccination strategy.
This is a modelling approach, and we are aware that determining
mosquito population densities is programmatically not feasible, or
very difficult to attain, on a routine basis.
We are also well aware that public health authorities do not
rely on any control strategy of Aedes-borne infections that is
based on vector control variables [27, 28]. Many years of attempt
to control Aedes mosquitoes by adulticides, larvicides, by
search-and-destroy breeding places have failed to reach any sig-
nificant impact on those diseases [29]. Moreover, none of the sur-
veillance methods used to monitor the risk of Aedes-borne
infections (House index, Container index, Bretau index, Pupa
index, adult population density using ovitraps, sticky traps,
human landing collections or any similar traps) correlate with
the number of cases [30]. However, the methods proposed in
[31] to estimate the density of mosquitoes from dengue incidence
data, assuming that certain parameters related to transmission are
known with reasonable accuracy, provide a good estimation of the
critical threshold that determines when R(t) crosses the unit
threshold at mcrit(t), as shown in Figure 4. As shown in
Figure 2, mcrit(t) in Salvador, this was reached 1 month before
the number of cases of ZIKV infections started to mount up.
This gives enough time to prepare and implement a mass vaccin-
ation campaign to curb the outbreak. On the other hand, if the
mosquitoes’ density threshold is not adopted by any reason as a
criterion to trigger a vaccination campaign, then vaccination
should start at most at the notification of the first case, although
at this time many cases would already be occurring, given the
high number of asymptomatic infections in Zika [31]. Once a vac-
cination campaign is initiated, the optimum strategy consists,
according to our model, in continuing vaccinating the target
population in a concentrated effort to reach a minimum of 25%
coverage in the period of 1 month. This, as shown in Figure 3,
would be enough to reach the herd immunity threshold.
However, as in real life, the implementation of a vaccine strategy
after notification of one single Zika case would take longer, the
coverage rate would need to be higher and the effectiveness of
the strategy less than optimum.
Fig. 5. Vaccination effectiveness as a function of the
moment (t0) the campaign starts.
Fig. 6. Vaccination effectiveness as a function of vaccin-
ation coverage. Continuous line represents 1 month of
duration and dotted line represent 6 months of dur-
ation. The continuous horizontal line marks the herd
immunity threshold from R0≅ 2.3.
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It is possible that public health authorities decide for a target
vaccination (e.g. women of reproductive age only), rather than
the universal campaign aiming both sexes and all age groups.
Hence, for instance, vaccinating women of reproductive ages
could be a possibility not considered here. However, any modifi-
cation from the universal vaccination campaign simulated in this
work could be easily incorporated in the model. The novelty of
our approach is on determining the optimum moment to start
the vaccination strategy and the duration of such an intervention
rather than the nature of the strategy.
Finally, we would like to stress the fact that, even in the absence
of a safe and efficacious vaccine, the theoretical model presented
can help the designing of an optimum strategy to control ZIKV
outbreaks the moment a future vaccine is ready to be used. Our
model proposes an interesting surveillance method in which,
from the incidence of dengue, an endemic infection in regions
that suffered ZIKV outbreaks, one can determine the exact
moment the mosquitoes’ density crosses the threshold of immi-
nent risk of an epidemic.
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